abstract |
The present invention provides compositions and methods for reducing flushing in a patient. In addition, compositions and methods are provided for increasing HDL and/or HDL-2b levels in a patient. In some embodiments, the compositions include an adipocyte G-protein antagonist, a PPAR-α agonist, and a PPAR-γ agonist in amounts effective in to provide a synergistic therapeutic HDL increasing effect, and/or a synergistic therapeutic HDL-2b increasing effect. |